CG
Insider
Carl L Gordon
DirectorCarl L Gordon (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in BlossomHill Therapeutics, Inc. Common Stock (BLSM). Across 2 priced purchase filings, the average 21-session return was +56.2% from execution and +52.9% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SCTX (1,000,000 sh × $15.00, as filed), executed Jul 27.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+56.2%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+52.9%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$25.0M
shares × price, as filed
Last traded
Aug 10
Filed Aug 12
Median ADV $19.6M across their filed names
Open performance→Volume by month
Buys $27.0M
Sells $5.7M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
BLSM
BlossomHill Therapeutics, Inc. Common Stock
BLSM · 1 buy · 0 sells
1 filing
CMPX
CMPX
CMPX · 0 buys · 1 sell
1 filing
MBX
MBX
MBX · 1 buy · 0 sells
1 filing
SCTXRecent filings
BLSMPURCHASE
BlossomHill Therapeutics, Inc. Common Stock
View filing →
$10.0M625,000 sh × $16.00
Exec Aug 10
Filed Aug 12 · 4:46 PM ET SCTXPURCHASE Scribe Therapeutics Inc. View filing → $15.0M
1,000,000 sh × $15.00
Exec Jul 27
Filed Jul 29 · 6:50 PM ET CMPXSALE Compass Therapeutics, Inc. View filing → $5.7M
3,571,428 sh × $1.59
Exec Apr 9 2025
Filed Apr 11 2025 · 5:30 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $2.0M
190,672 sh across 4 lots
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $12.0M
750,000 sh across 2 lots
Exec Sep 16 2024
Filed Sep 17 2024 · 5:30 PM ET